Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 7/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.38 |
| ▸ | CCKAR | P32238 | 1/20 | 0.37 |
| ▸ | CTSL | P07711 | 2/20 | 0.36 |
| ▸ | CTSS | P25774 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7565325 | 1.00 | CTSK (0.45) | CTSKMAPK1CACNA1BCCKARCTSL | |
| SCHEMBL7207130 | 0.89 | CTSK (0.45) | CTSKCACNA1BCTSLCTSSKMT2A | |
| SCHEMBL7036592 | 0.87 | CTSK (0.51) | CTSKMAPK1CACNA1BCCKARCTSL | |
| SCHEMBL4902191 | 0.87 | CTSK (0.51) | CTSKMAPK1CACNA1BCCKARCTSL | |
| SCHEMBL5099105 | 0.85 | CTSK (0.47) | CTSKMAPK1 | |
| SCHEMBL5099103 | 0.85 | CTSK (0.47) | CTSKMAPK1 | |
| SCHEMBL5099268 | 0.84 | CTSK (0.41) | CTSKCACNA1BCTSLCTSS | |
| SCHEMBL7426616 | 0.84 | CTSK (0.44) | CTSKCACNA1BCTSLCTSSMEN1 | |
| SCHEMBL5582054 | 0.84 | CACNA1B (0.47) | CTSKCACNA1BKMT2A | |
| SCHEMBL5582055 | 0.84 | CACNA1B (0.47) | CTSKCACNA1BKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1384713-B1 | 4-amino-azepan-3-one derivatives as protease inhibitors | SMITHKLINE BEECHAM CORP (US) | 2008-10-15 | — | — | EP | disclosed |
| US-7405209-B2 | e.g. 2-Benzyloxycarbonylamino-4-methyl-pentanoyl)-3-oxo-azepan-4-ylcarbamoyl}carbamic acid benzyl ester; protease inhibitors like cathepsin K; osteoporosis, osteo- and rheumatoid arthritis and periodontal disease; inhibiting excessive cartilage or matrix degradation | SMITHKLINE BEECHAM CORPORATION (US) | 2008-07-29 | — | — | US | disclosed |
| US-20050256104-A1 | substituted 1,1,4-1l6-trioxo[1,2]thiazepan-4-ylamide-derived protease inhibitors which inhibit the likes of cathepsin K; treating osteoporosis, osteo- and rheumatoid arthritis and periodontal disease; inhibiting excessive cartilage or matrix degradation | SMITHKLINE BEECHAM CORPORATION | 2005-11-17 | — | — | US | disclosed |
| EP-1384713-A1 | 4-amino-azepan-3-one derivatives as protease inhibitors | SmithKline Beecham Corporation (US) | 2004-01-28 | — | — | EP | disclosed |
| US-20040002487-A1 | Protease inhibitors | MARQUIS ROBERT WELLS (US) | 2004-01-01 | — | — | US | disclosed |
| US-20030225061-A1 | Protease inhibitors | MARQUIS ROBERT WELLS (US) | 2003-12-04 | — | — | US | disclosed |
| US-20030144175-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2003-07-31 | — | — | US | disclosed |
| US-6596715-B1 | Pharmaceutically acceptable salt, hydrate or solvate thereof, which is an inhibitor of cysteine proteases, particularly cathepsin K, and is useful in the treatment of diseases in which inhibition of bone loss or of cartilage degradation is a | SMITHKLINE BEECHAM CORPORATION | 2003-07-22 | — | — | US | disclosed |
| US-6583137-B1 | Cysteine proteases, particularly cathespin K, inhibition of bone loss, cartilage degradation; quinoxaline-2-carboxylic acid ((S)-3-methyl-1-((2,2',4-trideuterio)-3-oxo-1-(1-oxy-pyridine-2-sulfonyl) -azepan-4-ylcarbamoyl)-butyl)amide) | SMITHKLINE BEECHAM CORPORATION | 2003-06-24 | — | — | US | disclosed |
| US-6534498-B1 | Compound which is an inhibitor of cysteine proteases, particularly cathepsin K, and is useful in the treatment of diseases in which inhibition of bone loss or of cartilage degradation is a factor. | SMITHKLINE BEECHAM CORPORATION | 2003-03-18 | — | — | US | disclosed |
| US-20020147188-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2002-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225061-A1 | Protease inhibitors | CTSK, MMP13, CTSZ | CTSK 1/4885MAPK1 2727/4885CACNA1B 4138/4885 |
| US-20050256104-A1 | substituted 1,1,4-1l6-trioxo[1,2]thiazepan-4-ylamide-derived protease inhibitors which inhibit the likes of cathepsin K; treating osteoporosis, osteo- and rheumatoid arthritis and periodontal disease; inhibiting excessive cartilage or matrix degradation | CTSK, CTSZ, CTSE | CTSK 1/4885MAPK1 2215/4885CACNA1B 4033/4885 |
| US-20020147188-A1 | Protease inhibitors | CTSK, MMP13, CTSZ | CTSK 1/4885MAPK1 2727/4885CACNA1B 4138/4885 |
| US-20040002487-A1 | Protease inhibitors | CTSK, MMP13, CTSZ | CTSK 1/4885MAPK1 2727/4885CACNA1B 4138/4885 |
| US-20030144175-A1 | Protease inhibitors | CTSK, MMP13, CTSZ | CTSK 1/4885MAPK1 2727/4885CACNA1B 4138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.